Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are publicly traded shares of companies that research, develop and commercialize products using living organisms or biological processes—ranging from novel drug therapies and vaccines to genetic tests and agricultural biotech. Their share prices often exhibit high growth potential and volatility, driven largely by clinical trial results, regulatory approvals and patent lifecycles. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded up $4.29 during trading hours on Friday, reaching $435.02. The stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The stock has a fifty day moving average of $409.39 and a 200 day moving average of $476.23. The stock has a market cap of $164.22 billion, a P/E ratio of 25.51, a price-to-earnings-growth ratio of 2.31 and a beta of 0.77. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $2.68 during trading hours on Friday, reaching $192.32. The stock had a trading volume of 4,990,162 shares, compared to its average volume of 6,311,659. The stock has a fifty day moving average of $187.01 and a 200 day moving average of $189.05. The stock has a market cap of $339.71 billion, a P/E ratio of 81.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.48. AbbVie has a 52-week low of $163.81 and a 52-week high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
NYSE DHR traded down $0.71 during trading hours on Friday, reaching $204.80. The stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,508,130. The stock has a fifty day moving average of $196.05 and a 200 day moving average of $206.30. The stock has a market cap of $146.57 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43.
Read Our Latest Research Report on DHR
Veeva Systems (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
NYSE VEEV traded down $5.82 during trading hours on Friday, reaching $275.82. The stock had a trading volume of 1,660,228 shares, compared to its average volume of 1,171,159. The stock has a fifty day moving average of $266.10 and a 200 day moving average of $239.52. The stock has a market cap of $45.07 billion, a P/E ratio of 58.44, a price-to-earnings-growth ratio of 2.19 and a beta of 0.98. Veeva Systems has a 52-week low of $177.41 and a 52-week high of $291.69.
Read Our Latest Research Report on VEEV
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
NASDAQ VRTX traded down $10.68 during trading hours on Friday, reaching $468.85. The stock had a trading volume of 892,738 shares, compared to its average volume of 1,426,652. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market cap of $120.40 billion, a P/E ratio of -119.60 and a beta of 0.41. The stock has a fifty day moving average of $447.71 and a 200 day moving average of $460.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65.
Read Our Latest Research Report on VRTX
Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Alnylam Pharmaceuticals stock traded down $7.70 during mid-day trading on Friday, hitting $314.94. The company had a trading volume of 1,081,877 shares, compared to its average volume of 855,444. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $333.70. The company's fifty day moving average is $301.17 and its 200-day moving average is $268.95. The company has a market capitalization of $41.07 billion, a price-to-earnings ratio of -150.69 and a beta of 0.23.
Read Our Latest Research Report on ALNY
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora stock traded down $2.25 during mid-day trading on Friday, hitting $295.07. The company had a trading volume of 970,795 shares, compared to its average volume of 1,512,862. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. Cencora has a 12-month low of $218.65 and a 12-month high of $309.35. The company's fifty day moving average is $291.91 and its 200-day moving average is $269.98. The company has a market capitalization of $57.19 billion, a price-to-earnings ratio of 34.23, a P/E/G ratio of 1.46 and a beta of 0.57.
Read Our Latest Research Report on COR
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
